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Summary
The blood-brain barrier (BBB) limits entry of blood-derived products, pathogens and cells into the 
brain that is essential for normal neuronal functioning and information processing. Post-mortem 
tissue analysis indicates BBB damage in Alzheimer’s disease (AD). The timing of BBB 
breakdown remains, however, elusive. Using an advanced dynamic contrast-enhanced magnetic 
resonance imaging protocol with high spatial and temporal resolutions to quantify regional BBB 
permeability in the living human brain, we show an age-dependent BBB breakdown in the 
hippocampus, a region critical for learning and memory that is affected early in AD. The BBB 
breakdown in the hippocampus and its CA1 and dentate gyrus subdivisions worsened with mild 
cognitive impairment that correlated with injury to BBB-associated pericytes, as shown by the 
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cerebrospinal fluid analysis. Our data suggest that BBB breakdown is an early event in the aging 
human brain that begins in the hippocampus and may contribute to cognitive impairment.
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Introduction
Neuronal computation and normal functioning of the central nervous system (CNS) requires 
tight control of the chemical composition of the neuronal ‘milieu’ that is maintained by the 
blood-brain barrier (BBB) (Iadecola, 2004; Zlokovic, 2008, 2011; Iadecola, 2013). Brain 
endothelial cells and perivascular mural cells, pericytes, form the BBB which limits entry of 
neurotoxic plasma-derived proteins, circulating metals, pathogens, red blood cells and 
leucocytes into the brain. Studies in murine transgenic models have shown that a chronic 
BBB breakdown leads to accumulation of blood-derived neurotoxic proteins in the CNS 
including fibrin, thrombin, hemoglobin, iron-containing hemosiderin, free iron and/or 
plasmin (an extracellular matrix-degrading enzyme) causing progressive neurodegeneration 
with loss of neurons mediated by either direct neuronal toxicity, oxidant stress and/or 
detachment of neurons from their supporting extracellular matrix (Daneman et al., 2010; 
Armulik et al., 2010; Bell et al., 2010, 2012; Winkler et al., 2012, 2014).
Alzheimer’s disease (AD) is characterized by selective neuronal vulnerability resulting in 
progressive loss of memory (LaFerla, 2012). Post-mortem studies have shown BBB damage 
in AD including accumulation in the hippocampus and cortex of blood-derived proteins 
(e.g., immunoglobulins, albumin, fibrinogen, and thrombin) (Fiala et al., 2002; Salloway et 
al., 2002; Zipser et al., 2007; Ryu et al., 2009; Hultman et al., 2013; Sengillo et al., 2013) 
and degeneration of BBB-associated pericytes (Sengillo et al., 2013; Farkas and Luiten, 
2001; Baloyannis and Baloyannis, 2012). Brain imaging studies have shown microbleeds 
and accumulation of iron in AD (Cullen et al., 2005; Goos et al., 2009; Zonneveld, 2014), 
particularly in the hippocampus (Raven et al., 2013). Some studies using the cerebrospinal 
fluid (CSF) to plasma ratio of blood-derived albumin, reported BBB damage in AD 
particularly associated with vascular risk factors (Blennow et al., 1990; Bowman et al., 
2012) or in individuals at a genetic risk for AD (Halliday et al., 2013). At what stage BBB 
breakdown occurs in the living human brain and whether it contributes to cognitive 
impairment remains, however, controversial.
Here, we used an advanced dynamic contrast-enhanced magnetic resonance imaging (DCE-
MRI) and post-processing analysis with improved spatial and temporal resolutions to 
quantify the BBB regional permeability Ktrans constant in the living human brain in 
individuals with no cognitive impairment (NCI) and mild cognitive impairment (MCI). 
Compared to a previous approach limited to measurements of BBB permeability in the white 
matter (WM) (Taheri et al., 2011a, 2011b, 2013), the current method allows simultaneous 
measurements of BBB Ktrans permeability in different grey and WM regions. Additionally, 
we analyzed CSF biomarkers of BBB breakdown, injury to brain vascular cells including 
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pericytes and endothelial cells, inflammatory response, neuronal injury (i.e., tau and pTau) 
and amyloid β-peptides (Aβ). We found an age-dependent BBB breakdown in the 
hippocampus, a region involved in learning and memory (Squire, 1992) that is damaged 
early in AD (Braak et al., 1993; Mu and Gage, 2011; Whitwell et al., 2012). The BBB 
breakdown in the hippocampus worsened with MCI that correlated with measures of injury 
to BBB-associated pericytes.
Results
BBB breakdown in the hippocampus during normal aging
We studied twelve CNS regions including hippocampus and its subdivisions CA1, CA3 and 
dentate gyrus (DG), different cortical regions, subcortical regions (e.g., thalamus, striatum, 
and caudate nucleus) and the WM regions including corpus callosum and internal capsule 
(Fig. 1A–B), and generated regional Ktrans BBB permeability maps for each individual using 
a modified Patlak linearized regression mathematical analysis (Patlak and Blasberg, 1985) 
(Fig. 1C). We determined in each individual the arterial input function (AIF) from the 
common carotid artery instead of using an average value from the superior sagittal venous 
sinus to determine tracer concentration in blood (Taheri et al., 2011a, 2011b, 2013; Larsson 
et al., 2009). Individual AIF measurements are important particularly if the studied 
population diverges by age as changes in blood volume and flow may affect AIF and the 
Ktrans measurements.
Unexpectedly, we found that NCI individuals (Table 1) have an age-dependent progressive 
loss of BBB integrity in the hippocampus, as shown by an age-dependent increase in the 
Ktrans values in the entire hippocampus, its CA1 region and DG, but not the CA3 region 
(Fig. 1D–G). No significant BBB changes during aging were found in cortical (e.g., frontal 
cortex, temporal cortex) or subcortical (e.g., thalamus, striatum) regions except for the 
caudate nucleus (Supplementary Fig. S1A–E). Surprisingly, we did not find significant age-
dependent changes in the BBB in subcortical WM fibers, corpus callosum and internal 
capsule (Supplementary Fig. S1F–H), even though WM is believed to be affected by 
vascular changes early in AD (Iadecola, 2013; Yoshita et al., 2006). Collectively, our data 
suggest that early vascular leakage in the aging human brain begins in the hippocampus that 
normally shows the highest barrier properties (i.e., the lowest Ktrans values) compared to 
other brain regions.
Accelerated BBB breakdown in the hippocampus in individuals with MCI
Next, we compared the BBB permeability in young NCI and older NCI (both CDR=0), and 
MCI (CDR=0.5) groups (Fig. 2; Table 1). We found a significant increase in the BBB 
permeability Ktrans values in the hippocampus (Fig. 2A) and its CA1 and DG regions, but 
not CA3, by 41%, 107% and 48% in the older compared to the young NCI group, and by 
24%, 53% and 27% in MCI compared to age-matched older NCI controls, respectively (Fig. 
2B–E). In contrast, there were no significant differences in the BBB permeability in cortical, 
subcortical and WM regions between young and older NCI, and/or MCI and age-matched 
older NCI participants (Supplementary Table 1), except for an increase in the caudate 
nucleus in older compared to young NCI group. We did not find significant changes in 
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hippocampal volumes between the studied groups determined on coronal T2-weighted MR 
images (Fig. 3).
To validate our method, we studied multiple sclerosis (MS) cases with established BBB 
breakdown in the WM, as reported (Taheri et al., 2011b), as an additional neurological 
control. MS cases had a diagnosis of the relapsing remitting MS and met McDonald Criteria 
(Polman et al., 2011). We selected younger MS cases without cognitive complaints that 
were age-matched to younger NCI controls (Table 1). The MS patients did not show 
changes in the Ktrans values in the hippocampus or hippocampal subregions (Fig. 2B–E), 
neither in other CNS grey matter regions (Supplementary Table 1). They had, however, 
increased BBB permeability in the total WM, corpus callosum and internal capsule 
compared to age-matched younger NCI group by 32%, 26% and 23% (p<0.001), 
respectively (Supplementary Table 1), consistent with the reported BBB alterations in the 
WM in MS (Taheri et al., 2011b). Our data extend importantly previous findings by showing 
no changes in the BBB integrity in the hippocampus and other studied grey matter regions in 
MS.
Molecular biomarker CSF analysis
A significant 30% increase in the CSF/plasma albumin ratio (Blennow et al., 1990; Bowman 
et al., 2012; Halliday et al., 2013) additionally confirmed BBB breakdown in MCI 
individuals compared to age-matched NCI controls (Supplementary Fig. S2A). The increase 
in the CSF/plasma albumin ratio correlated with an increase in the Ktrans values in the 
hippocampus and its CA1 and DG subregions (Supplementary Fig. S2B–D) that showed an 
increase in the BBB permeability in MCI compared to age-matched NCI controls (Fig. 2B, 
C and E).
Next, we studied correlations between Ktrans values and CSF levels of soluble platelet-
derived growth factor receptor β (sPDGFRβ). PDGFRβ is an established marker of the BBB-
associated pericytes (Armulik et al., 2010; Bell et al., 2010, 2012; Winkler et al., 2011) that 
play a key role in maintaining the BBB integrity (Zlokovic, 2008, 2011; Iadecola, 2013; 
Daneman et al., 2010; Armulik et al., 2010; Bell et al., 2010, 2012; Winkler et al., 2012). 
Pericytes degenerate in AD (Sengillo et al., 2013; Farkas and Luiten, 2001; Baloyannis and 
Baloyannis, 2012) and have a key role in BBB clearance of Alzheimer’s toxin amyloid β-
peptide (Aβ) (Sagare et al., 2013). Pericytes die when Aβ intracellular accumulation 
overrides their Aβ clearance capability (Sagare et al., 2013) and when exposed to hypoxia. 
Both conditions are associated with shedding of the soluble form of the receptor (sPDGFRβ) 
from primary human cultured pericytes (Supplementary Fig. S3A–D). Furthermore, 
sPDGFRβ levels were increased by 115% in MCI compared to age-matched NCI controls 
(Fig. 4A). There was a positive correlation between sPDGFRβ CSF levels and the Ktrans 
values in the hippocampus including its CA1 and DG subdivisions (Fig. 4B–D) that showed 
increased BBB permeability in MCI compared to NCI individuals (Fig. 2B, C and E).
To validate CSF sPDGFRβ as a marker of pericyte injury in vivo, we studied sPDGFRβ CSF 
levels in 16-month-old pericyte-deficient Pdgfrβ+/− mice which develop ~45–50% loss of 
brain pericytes (Bell et al., 2010) and 16-month-old Alzheimer’s Tg2576 mice which 
develop an age-dependent pericyte loss from 17% at 9 months of age (Sagare et al., 2013) to 
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35% at 18 months of age (Park et al., 2013). There was a significant 289% and 58% increase 
in sPDGFRβ CSF levels in Pdgfrβ+/− mice and Tg2576 mice, respectively, compared to 
their corresponding littermate controls (Fig. 4E–F), indicating that sPDGFRβ is a reliable 
CSF marker of pericytes injury in mice.
The CSF analysis revealed no injury to other cell types in the neurovascular unit (Iadecola, 
2004; Zlokovic, 2008, 2011) in NCI or MCI including endothelial cells as shown by 
unaltered CSF levels of biomarkers of endothelial cell injury such as soluble intercellular 
adhesion molecule-1 (sICAM-1) and vascular cell adhesion molecule-1 (sVCAM-1) 
(Iadecola, 2004; Zlokovic, 2008); no change in the inflammatory response as shown by 
unaltered CSF levels of several studied cytokines (e.g., interleukins IL-2, IL-6, and IL-8, 
tumor necrosis factor-α, and interferon-γ); no change in neuronal injury (e.g., tau and pTau) 
and Aβ (e.g., Aβ38, Aβ40 and Aβ42); and no change in matrix metalloproteinase-9 that is 
involved in degradation of the BBB tight junction and the basement membrane proteins of 
the vessel wall (Bell et al., 2012; Halliday et al., 2013) (Supplementary Fig. S4).
Discussion
We developed an advanced DCE-MRI approach and post-processing analysis resulting in 
improved spatial resolution and signal-to-noise ratio (SNR) of the Ktrans BBB maps with the 
analysis of the arterial input function in each individual allowing for accurate measurements 
of the regional BBB permeability in the living human brain in different grey and WM 
regions. For example, our high resolution hippocampal imaging allows for characterization 
of the Ktrans BBB values not only in the hippocampus, but also in the hippocampal subfields. 
In comparison, studies on the blood-brain tumor barrier permeability (Larsson et al., 2009) 
or BBB in stroke (Aksoy et al., 2013) do not generally require spatial resolution or SNR as 
high as the present study, as changes in the barrier permeability in brain tumors or after 
stroke are typically one order of magnitude or more higher than the presently measured BBB 
changes during normal aging, aging associated with MCI and/or possibly other 
neurodegenerative conditions. The BBB permeability Ktrans values in the hippocampus and 
cortex and other brain regions in young NCI individuals were within a range of previously 
reported BBB Ktrans values to small inert polar molecules in mammals including rodents 
(Zlokovic, 2011; Bell et al., 2010; Deane et al., 2003).
We show that the BBB breakdown during normal aging occurs initially in the hippocampus, 
a region critical for learning and memory. The BBB breakdown was more pronounced in 
MCI compared to age-matched neurologically intact controls raising a possibility that it 
might contribute to early cognitive impairment. Interestingly, our data show that the BBB 
integrity in other brain regions including cortical and subcortical regions or the WM remains 
relatively unaffected during normal aging or aging associated with MCI. Although we did 
not find significant changes in hippocampal volumes between the young and older NCI and 
MCI individuals, it is possible that an early and progressive increase in the BBB 
permeability, as we show in the hippocampus in older NCI and MCI individuals, might 
precede hippocampal atrophy seen later in AD (Whitwell et al., 2012; Apostolova et al., 
2010) particularly in MCI progressing to AD. This would be similar to findings in animal 
models with a chronic BBB disruption showing that vascular leakages over time lead to 
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hippocampal and cortical atrophy, loss of neurons and progressive behavioral changes (Bell 
et al., 2010, 2012; Winkler et al., 2012, 2014).
Findings in murine models of a small vessel brain disease (Daneman et al., 2010; Armulik et 
al., 2010; Bell et al., 2010, 2012) and human post-mortem AD studies (Fiala et al., 2002; 
Salloway et al., 2002; Zipser et al., 2007; Ryu et al., 2009; Hultman et al., 2013; Sengillo et 
al., 2013) have shown that BBB breakdown leads to tissue accumulation of potentially 
neurotoxic blood-derived products that normally do not enter the brain, but can damage 
neurons when the vessels become leaky. We show that pericyte injury and possibly early 
degeneration correlates with increased BBB permeability within the hippocampus, a region 
known to be affected by pericyte loss and BBB breakdown on post-mortem tissue analysis 
in AD (Sengillo et al., 2013). Although, our CSF biomarkers analysis did not show 
endothelial cell injury, involvement of inflammatory cytokines and/or direct vasculotoxic 
effects of Aβ in MCI, it is possible that some of these factors could play a role in magnifying 
BBB damage at later disease stages during progression to dementia due to AD, as they all 
were shown to alter BBB permeability in experimental models (Zlokovic, 2011).
In summary, our data suggest loss of cerebrovascular integrity during normal aging and 
aging associated with MCI that begins in the hippocampus which may contribute to early 
stages of dementia associated with AD.
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Fig. 1. Blood-brain barrier breakdown in the hippocampus in the living human brain during 
normal aging
(A–B) A dynamic contrast enhanced magnetic resonance imaging was used to quantify the 
blood-brain barrier (BBB) regional permeability Ktrans constant in 12 regions-of-interest in 
the gray and white matter in the living human brain (A) including subdivisions of the 
hippocampus (B). (C) Representative BBB Ktrans maps of the whole brain (left) and the 
hippocampus (right) in a young participant with no cognitive impairment. (D–G) Age-
dependent increase in the BBB permeability Ktrans constant in the entire hippocampus, its 
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CA1 region and dentate gyrus, but not CA3 region. Single data points for the Ktrans constant 
from 24 individuals with no cognitive impairment (both genders, ages 23–91; see Table 1) 
were plotted against age; r = Pearson’s coefficient; P, significance; NS, non-significant. See 
also Supplementary Figure S1.
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Fig. 2. Blood-brain barrier breakdown in the hippocampus during normal aging and aging 
associated with mild cognitive impairment
(A) Representative Ktrans maps within the hippocampus in young and older individuals with 
no cognitive impairment (NCI) and mild cognitive impairment (MCI). MS, a multiple 
sclerosis case with no cognitive impairment. (B–E) A progressive significant increase in the 
BBB permeability constant Ktrans in older compared young NCI group and MCI compared 
to older NCI group in the entire hippocampus, CA1 region and dentate gyrus. MS group was 
compared with age-matched young NCI group. Boxplots represent the median (dark 
horizontal line), with the box representing the 25th and 75th percentiles, the whiskers the 5th 
and 95th percentiles. P, significance by ANOVA followed by Tukey’s post hoc tests; NS, 
non-significant. NCI, young (n=6, ages 23–47, both genders); NCI, older (n=18, ages 55–91, 
both genders); MCI (n=20, ages 55–85, both genders); MS (n=19, ages 26–53, both 
genders). See Table 1 and Supplementary Figure S2.
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Fig. 3. Hippocampus volume in the studied groups
Hippocampus volume was determined on T2-weighted images in individuals with no 
cognitive impairment (NCI), with mild cognitive impairment (MCI), and multiple sclerosis 
(MS) cases with no cognitive impairment. NS, non-significant by ANOVA followed by 
Tukey’s post hoc tests. NCI, young (n=6, ages 23–47, both genders); NCI older (n=18, ages 
55–91, both genders); MCI (n=20, ages 55–85, both genders); MS (n=19, ages 26–53, both 
genders). See Table 1.
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Fig. 4. Soluble platelet-derived growth factor receptor β in the cerebrospinal fluid in humans and 
mice
(A) Elevated sPDGFRβ levels in the CSF in individuals with mild cognitive impairment 
(MCI; n=17) compared to age-matched group with no cognitive impairment (NCI, older; 
n=14). (B–D) Single data points for sPDGFRβ CSF levels from 31 individuals with NCI 
(n=14, black) or MCI (n=17, red) plotted against the Ktrans constant in the hippocampus (B), 
its CA1 region (C), and dentate gyrus (D); r = Pearson’s coefficient; P, significance. (E–F) 
sPDGFRβ CSF levels in 16-month-old Pdgfrβ+/− mice and Pdgfrβ+/+ controls (C) and 16-
month-old Tg2576 mice compared to age-matched littermate controls (D). In C and D, n=5 
mice per group. P, significance by a Student’s t-test. See also Supplementary Figures S3 and 
S4.
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Table 1
Patients' Demographic Information
NCI, young NCI, older MCI MS
Clinical Dementia Rating scale 0 0 0.5 0
Number of participants 6 18 21 19
Female, % 50 55.6 52.4 63.2
Age range 23–47 55–91 55–85 26–53
DCE-MRI 6/6 18/18 20/21 19/19
Lumbar puncture 0/6 15/18 17/21 0/6 15/18 17/21 0/19
Age at lumbar puncture, Mean (SO) N/A 73.2 (10.6) 72.0 (8.5) N/A
NCI, no cognitive impairment; MCI, mild cognitive impairment; MS, multiple sclerosis; DCE-MRI, dynamic contrast-enhanced magnetic 
resonance imaging; SD, standard deviation; N/A, not applicable.
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